**Author details**

Min Yao1,2† , Wenjie Zheng2† , Li Wang1 , Miao Fang2† , Dengfu Yao<sup>2</sup> \* and Zhizheng Dong3

\*Address all correspondence to: yaodf@ahnmc.com

1 Medical School of Nantong University, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China

[6] Hollebecque A, Malka D, Ferte C, Ducreux M, Boige V. Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons. European Journal of

Oncogenic Secretory Clusterin: A Promising Therapeutic Target for Hepatocellular Carcinoma

http://dx.doi.org/10.5772/intechopen.71007

143

[7] Choi SH, Park JY. Regulation of the hypoxic tumor environment in hepatocellular carcinoma using RNA interference. Cancer Cell International. 2017;**17**(1):3-11 [PMID: 28053598]

[8] Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;**150**(4):835-853 [PMID:

[9] Juárez-Hernández E, Motola-Kuba D, Chávez-Tapia NC, Uribe M, Barbero Becerra V. Biomarkers in hepatocellular carcinoma: An overview. Expert Review of Gastroenterology

[10] Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clinical Cancer Research. 2010;**16**(4):1088-1093 [PMID:

[11] Trougakos IP, Djeu JY, Gonos ES, Boothman DA. Advances and challenges in basic and translational research on clusterin. Cancer Research. 2009;**69**(2):403-406 [PMID:

[12] Yao DF, Huang ZW, Chen SZ, Huang JF, Lu JX, Xiao MB, Meng XY. Diagnosis of hepatocellular carcinoma by quantitative detection of hepatoma-specific bands of serum gamma-glutamyl transferase. American Journal of Clinical Pathology. 1998;**110**(6):743-

[13] Yao DF, Jiang DR, Huang ZW, Lu JX, Tao QY, Yu ZJ, Meng XY. Abnormal expression of hepatoma specific γ-glutamyl transferase and alteration of γ-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer. 2000;**88**(4):761-769

[14] Yao M, Wang L, Fang M, Zheng W, Dong Z, Yao D. Advances in the study of oncofetal antigen glypican-3 expression in HBV-related hepatocellular carcinoma. Bioscience

[15] Wang L, Pan L, Yao M, Cai Y, Dong Z, Yao D. Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma.

[16] Wu W, Yao DF, Yuan YM, Fan JW, Lu XF, Li XH, Qiu LW, Zong L, Wu XH. Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases Interna-

[17] Pan LH, Yao M, Zheng WJ, Gu JJ, Yang XL, Qiu LW, Cai Y, Wu W, Yao DF. Abnormality of Wnt3a expression as novel specific biomarker for diagnosis and differentiation of

hepatocellular carcinoma. Tumour Biology. 2016;**37**:5561-5568 [PMID: 26577850]

Cancer. 2015;**51**(3):327-339 [PMID: 25559615]

& Hepatology. 2017;**11**(6):549-558 [PMID: 28347162]

26795574]

20145158]

19147550]

749 [PMID: 9844586]

[PMID: 10679644]

Trends. 2016;**10**(5):337-343 [PMID: 27795482]

tional. 2006;**5**(4):538-544 [PMID: 17085339]

Oncotarget. 2016;**7**(27):42150-42158 [PMID: 27286460]

2 Institute of Clinical Oncology, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China

3 Department of Diagnostics, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China

† These authors contributed equally to this work.
